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Abstract
Background: The multiligand receptor megalin controls the brain uptake of a number of ligands, including insulin
and leptin. Despite the role of megalin in the transport of these metabolically relevant hormones, the role of
megalin at the blood–brain-barrier (BBB) has not yet been explored in the context of metabolic regulation.
Methods: Here we investigate the role of brain endothelial megalin in energy metabolism and leptin signaling
using an endothelial cell-specific megalin deficient (EMD) mouse model.
Results: We found megalin is important to protect mice from developing obesity and metabolic syndrome when
mice are fed a normal chow diet. EMD mice developed neuroinflammation, by triggering several pro-inflammatory
cytokines, displayed reduced neurogenesis and mitochondrial deregulation.
Conclusions: These results implicate brain endothelial megalin expression in obesity-related metabolic changes
through the leptin signaling pathway proposing a potential link between obesity and neurodegeneration.
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Background
Megalin, also called low-density lipoprotein receptor-
related protein-2 (LRP2) is a multiligand endocytic
receptor that belongs to the LRP family proteins [1].
Megalin is expressed at the blood brain barrier (BBB),
where it binds and internalizes a wide variety of ligands,
including hormones, such as leptin [2, 3] and insulin [4].
Interestingly, megalin binds amyloid-beta (Aβ) peptide
contributing to brain Aβ clearance, one of the histo-
pathological markers of Alzheimer’s disease (AD) hence
low megalin levels are related to AD pathology [5, 6].
Leptin is a canonical weight-regulatory hormone that
modulates body weight by reducing food intake and
increasing energy expenditure [7]. Its action is mediated
by interaction with the leptin receptor (ObR) that is
mainly expressed in the hypothalamus but also in other
cerebral regions, including cerebral cortex and hippo-
campus [8]. To reach these target areas, leptin binds to
the ObR once it passes through the BBB [9]. Thus, leptin
delivery into the central nervous system (CNS) seems to
represent a crucial step toward the regulation of food
intake and energy balance. We previously generated a
transgenic mouse model with lack of megalin in the
brain endothelial cells (EMD mice) [10]. We found that
EMD mice exhibited cortical neurodegeneration and
cognitive deficits, including increased anxiety and
impaired learning ability and recognition memory. These
results suggested that EMD mice could reproduce
several clinical features described in neurodegenerative
disorders.
In this study, we investigated the brain megalin-
mediated leptin signaling in the EMD mice. We found
that EMD mice exhibit mild obesity as a result of hyper-
phagia, increased adiposity, elevated leptin and insulin
plasma concentration, hypertriglyceridemia, impaired
glucose tolerance, and decreased hypothalamic leptin
signaling. Moreover, EMD mice lead to neuroninflamma-
tion, by triggering several pro-inflammatory cytokines,
and impaired neurogenesis. In summary, deletion of
megalin in brain endothelial cells was found sufficient and
necessary to promote obesity and activate obesity-induced
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A number of 12 male EMD mice were generated using
the Cre-Lox system under the control of the Tie2 as pre-
viously reported [10]. A number of 10 nontransgenic
littermates (i.e., Tie2-Cre−mice) were used as controls
(megalin flox/flox) and named as control mice. EMD and
control mice were grouped under a 12 h light: 12-h dark
schedule and allowed ad libitum access to food and
water. Body weight was monitored weekly throughout
the study. Daily food intake was calculated as the aver-
age intake of chow. At the end of the experiments,
animals were anesthetized with isoforane, blood was
drawn and perfused transcardially with saline buffer or
4% paraformaldehyde in 0.1-M phosphate buffer (PB,
pH 7.4) for biochemical and immunohistochemical ana-
lysis, respectively. Then, brain, liver, and adipose tissue
were collected for further processing and stored at −80 °C
until analysis. The liver and adipose tissue were previ-
ously weighed. Glucose tolerance test was assessed
prior to sacrifice. All animals were handled and cared
for according to the Council Directive 2010/63/UE of
22 September 2010.
Analytical procedures
Plasma concentrations of leptin and insulin were mea-
sured by ELISA using mouse standards according to the
manufacturer’s guidelines (mouse leptin ELISA kit; mouse
rat insulin ELISA kit, from R&D). Plasma triglycerides
(TG) were quantified using the commercially available kits
(Roche Molecular Biochemicals). Glucose tolerance test
was performed in 16-h-fasted animals. After collection of
a baseline sample, mice received an intraperitoneal (i.p.)
injection of glucose (2 g/kg body weight). Blood glucose
levels were detected after 15, 30, 60, and 120 min after
glucose injection, using a Compact Plus Glucose Meter
(Accu-Chek, Roche). Area under the curve (AUC) was
used to compare glucose tolerance between groups.
Immunohistochemistry
For immunohistochemistry assays, fixed brains were cut
on a vibratome (Leica Microsystems) at 30 μm, and
tissue sections were collected in cold 0.1 M PB, After
overnight incubation, primary antibody staining was
revealed using fluorescence-conjugated secondary anti-
bodies from Molecular Probes. Primary antibodies were:
rabbit anti-NeuN (Millipore), mouse anti-leptin receptor
(Obr, Santa Cruz Biotechnology), mouse anti-GFAP
(Sigma-Aldrich), mouse anti-phosphorylated STAT3
(pSTAT3, Cell Signaling), rabbit anti-ionized calcium-
binding adaptor molecule 1 (Iba1, Wako), goat anti-
doublecortin (DCX, Santa Cruz Biotechnology), and
mouse anti-polysialylated neural cell adhesion molecule
(PSA-NCAM, Chemicon). Fluorescent images were
obtained by laser confocal microscopy (Carl Zeiss-
LSM510) using the excitation lasers 405, 488, and 568
for DAPI, green, and red fluorescence, respectively. For
quantitative analysis of hypothalamic Obr+/NeuN+ neu-
rons and Obr+/GFAP+ astrocytes, double fluorescence
cells were counted, marked to prevent multiple counts,
and expressed as percentage of total GFAP+ or NeuN+
double-labeled cells. For quantitative analysis of hypo-
thalamic pSTAT3+/NeuN+ neurons, double fluorescence
cells were counted, marked to prevent multiple counts,
and expressed as percentage of total NeuN+ neurons.
The number of reactive microglial Iba1+ cells was esti-
mated by unbiased stereology method as previously
described [11]. GFAP+ area was stereologically analyzed
as described previously [12]. In addition, one series of
sections was used for double-labeling experiments using
DAPI nuclear staining (Sigma) and DCX as a marker of
neuronal progenitor cells. Using the Cell Counter program
of the NIH ImageJ software, we counted hippocampal
DCX+ cells of the captured confocal microphotographs.
Mitochondrial mass assessment
Control and EMD cortical sections were incubated with
the mouse primary antibody anti-ATP synthase β subunit
(Abcam, Cambridge, UK) targeting mitochondria. 4–5
high-resolution Z-stacks were acquired corresponding to
different regions from cortical tissue sections per animal
from each group (control = 10 and EMD= 12). The
method enabled adequate visualization of the mitochon-
drial network. The mitochondrial network fluorescence
and volume was identified and analyzed using the Volocity
software (PerkinElmer, Waltham, MA). The mitochondria
in cortex were set as 100% in mice control sections enab-
ling a comparison between different groups.
RNA extraction and PCR
Total RNA was isolated using Tripure reagent (Roche Diag-
nostics, Basel, Switzerland) and then reverse-transcribed
into cDNA using the Quantitect Enzyme Reverse Tran-
scriptase Kit (Qiagen) according to the manufacturer’s in-
structions. SYBR Green real-time RT-PCR was performed
with the Stratagene Mx3005P sequence detection system
(Agilent Technologies) using SensiMix SYBR Low-ROX
(Bioline, Luckenwalde, Germany). The primers used in the
RT-PCR to determine the expression levels of TNF, IL1β,
IL6, Socs3, Stat3, NPY, Actβ, and Rn18s were predesigned
and validated by Qiagen (QuantiTect Primer Assay) and
are presented in Additional file 1: Table S1. Threshold cycle
values were determined automatically using the software
supplied by Stratagene (MxPro Software 3.20). Primer spe-
cificity was verified by melt curve analysis. Relative gene
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expression was determined using the 2ΔΔCT method. All
values for gene expression following PCR analysis are
expressed as relative to reference genes content and re-
ferred to as relative expression.
Protein analyses
Cortical homogenates containing 20 μg of protein were
loaded on a 4–20% SDS-PAGE gel (BioRad) and trans-
ferred onto PVDF membranes (Millipore). They were
then incubated with an antibody cocktail targeting one
representative subunit of each of the five mitochondrial
complexes (MitoSciences, complex I subunit NDUFB8,
complex II-30 Da, complex III Core protein 2, complex
IV subunit I, complex V alpha subunit), and mouse anti-
mitofusin2 (Mfn2) (Abcam). Immunoreactive protein
was detected using an enhanced chemiluminescence re-
agent (ECL Clarity, Bio Rad). Densitometric quantifica-
tion was carried out with ImageQuant TL Image
Analysis software version 7.0 (LAS 4000, GE Health-
care). Protein loading was monitored using a mouse
monoclonal antibody against β-actin (Sigma-Aldrich).
Data analysis
Statistical analysis data are presented as mean ± SEM.
Post hoc comparisons between two groups were done
with Student’s t test. One-way ANOVA, followed by a
Tukey’s post hoc test, was used for comparing multiple
groups. All calculations were made using SPSS v15.0
software (Chicago, IL, USA). Statistical significance was
set at P < 0.05.
Detailed protocols are described in Supplemental Ex-
perimental Procedures.
Results
Endothelial-specific megalin deficiency leads to obesity
To investigate the impact of megalin knockdown in BBB
on energy balance homeostasis, body weight of EMD
and littermate control mice was monitored from wean-
ing until 20 weeks of age. Megalin deletion led to in-
creased body weight at 5 weeks (P < 0.05) that persisted
over time (Fig. 1a). In agreement with this, EMD mice
showed increased body adiposity index (BAI), defined as
the percentage of fat in the body (control = 1.8 ± 0.2%;
EMD = 2.7 ± 0.1%; P < 0.05; Fig. 1b). Along this observa-
tion, EMD mice exhibited increased cumulative food in-
take (control = 4.0 ± 0.1 g/day; EMD = 4.8 ± 0.4 g/day; P
< 0.05; Fig. 1c) and significantly higher relative weight
(weight ratio to body weight) of the liver control = 80.6
± 5.8 mg/g BW; EMD = 102.1 ± 3.3 mg/g BW P < 0.05;
Fig. 1d). Moreover, EMD mice displayed increased
plasma levels of leptin, (control = 7.5 ± 4.3 ng/ml; EMD
= 59.7 ± 27.5 ng/ml; P < 0.05; Fig. 1e), insulin (control =
1.7 ± 0.7 ng/ml ; EMD = 5.2 ± 1.6 ng/ml; P < 0.05; Fig. 1f ),
and triglycerides (control = 35.2 ± 4.9 mg/dl; EMD = 52.4
± 3.8 mg/dl; P < 0.01; Fig. 1g) compared to control mice.
These phenotypes were concomitant with reduced glu-
cose tolerance in the EMD compared to control mice as
evaluated in a glucose tolerance test (Fig. 1h, i). To-
gether, these results indicate that deletion of the trans-
porter megalin in brain endothelial cells leads to mild
obesity in mice.
Leptin signaling is disrupted in the hypothalamus of EMD
mice
The impact of leptin signaling on hypothalamus after
BBB megalin deletion was evaluated. It is known that
leptin binds to ObR leading to the phosphorylation of
STAT3 [11–13]. Reduced ObR immunoreactivity was
observed in hypothalamic neurons from 20-week-old
EMD mice compared to controls (control = 73.8 ± 6.1%;
EMD = 19.3 ± 3.8%; P < 0.01; Fig. 2a, b). Levels of
pSTAT3 were also reduced in hypothalamic neurons of
EMD compared to control mice (control = 45.1 ± 3.2%;
EMD = 18.9 ± 2.8%; P < 0.05; Fig. 2c, d). These results
suggest that the mild obese phenotype of EMD mice
could be a consequence of hypothalamic leptin resist-
ance. The ObR and pSTAT3 downregulation showed
above reflects leptin resistance in the EMD mice.
Megalin knock down in the BBB induces cortical and
hippocampal inflammation
The analysis of Iba-1 and GFAP fluorescence in cortical
and hippocampal sections reflected significantly higher
glial activation in the EMD mice when compared to the
control mice (Iba-1 fluorescence: in cortex, control =
100.0 ± 23.0%; EMD = 212.2 ± 28.4%; P < 0.01; in hippo-
campus, control = 100.0 ± 25.2%; EMD = 309.4 ± 42.1%;
P < 0.01; Fig. 3a, b; GFAP fluorescence: in cortex, con-
trol = 100.0 ± 15.8%; EMD = 193.5 ± 35.4%; P < 0.01; in
hippocampus, control = 100.0 ± 18.4%; EMD = 219.9 ±
22.4%; P < 0.01; Fig. 3c, d). Similar results were found in
hypothalamic sections showing increased glial activation
(Iba-1 fluorescence in hypothalamus: control = 100 ±
10%; EMD = 145 ± 10%; P < 0.002, Additional file 1: Fig.
S1 a, b; GFAP fluorescence in hypothalamus: control =
100 ± 5%; EMD = 171 ± 27%; P < 0.005, Additional file 1:
Figs. S1 c, d). A number of events related to pro-
inflammatory cytokines secretion can be observed after
microglial and astroglial activation in brain. The mRNA
expression analysis of pro-inflammatory cytokines
showed increased mRNA levels in the EMD mice group
compared to control mice of interleukin 1β (IL-1β)
(41.4%; P < 0.05 in cerebral cortex), interleukin-6 (IL-6)
(62.5%; P < 0.01 in cerebral cortex; and 113.9%; P < 0.05
in hippocampus) and tumor necrosis factor-α (TNF-α)
(72.7%; P < 0.05 in cerebral cortex; and 102.2%; P < 0.05
in hippocampus) (Fig. 3e). It is known that these pro-
inflammatory cytokines activate the STAT3 transcription
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factor. Densitometric analysis of pSTAT3 signal in cor-
tical sections showed increased phosphorylation levels in
EMD mice compared to wt (Figs. 3f, g) while the STAT3
expression levels remained unchanged (Fig. 3h). Add-
itionally, the mRNA expression of the suppressor of
cytokine signaling-3 (SOCS3) was found significantly re-
duced in the cortical and hippocampal sections from the
EMD mice compared to those sections from the control
group (39.72%; P < 0.05 in cerebral cortex; and 38.02%;
P < 0.05 in hippocampus; Fig. 3i). Moreover, the mRNA
expression of the orexigenic neuropeptide Y (NPY)
which is involved in the energetic balance regulation
along leptin, was found significantly increased in the
EMD mice cortical samples compared to the control
mice (69.6%; P < 0.050 (Fig. 3j). Accordingly, the leptin
levels in cortex from the the transgenic mouse model
were found reduced compared to control (control =
1037.1 ± 74.1 pg/ml; EMD = 906.5 ± 25.0 pg/ml; p < 0.05;
Fig. 3k). The analysis of the pSTAT3 signal, NPY expres-
sion, and leptin levels in the hippocampus reported no
significant changes (Additional file 1: Fig. S2).
Additionally, increased glial activation affects the neuro-
genesis. Indeed, the analysis of doublecortin (DCX)-positive
immature neurons and the polysialic acid-neural cell adhe-
sion molecule (PSA-NCAM)-positive mature neurons in
the dentate gyrus of the hippocampus, revealed that
Fig. 1 Analysis of energy homeostatic and metabolic parameters. EMD (n = 12) and control (n = 10) mice were evaluated for 20 weeks. a Weekly
body weight, measured along 20 weeks, was significantly increased in EMD mice compared to wt mice. b Adiposity index was significantly
increased in EMD mice compared to wt mice. c Daily food intake was increased in EMD mice compared to wt mice. d Relative weight of liver
was reduced in EMD mice compared to wt mice. (e–g) e Plasma levels of leptin, f insulin, and g triglycerides were significantly increased in EMD
mice compared to wt mice. h Glucose tolerance was assessed over 120 min in EMD mice compared to wt mice. i The area under curve (AUC)
was calculated for respective groups and used for statistical analysis. TG triglycerides. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01;
Student’s t test.
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neurogenesis is impaired in the EMD mice compared to
control (DCX+: control = 35.4 ± 4.6 cells, EMD= 14.0 ± 2.7
cells, P < 0.01, Additional file 1: Fig. S3 a, b; PSA-NCAM+:
control = 25.6 ± 2.8 cells; EMD= 6.0 ± 1.7 cells; P < 0.05;
Additional file 1: Figs. S3c, d).
BBB megalin deletion is related to mitochondrial
impairment
Obesity has been linked to mitochondrial alterations,
[14, 15]. To evaluate possible mitochondrial impair-
ments in our experimental model, the protein levels of
representative subunits from the ETC and OXPHOS
complexes were analyzed by immunoblotting in cortical
samples from the wt and the EMD mice. A significant re-
duction in the complex I component was found in the
EMD mice cortical tissue compared to those from the wt
(Fig. 4a). Downregulated complexes could indicate energy
metabolism disturbances and cells may compensate this
deficit by mitochondrial biogenesis stimulation [16]. Indeed,
the analysis of cortical sections in the EMD mice revealed
increased mitochondrial mass compared to the control
(control = 100 ± 4%; EMD= 146 ± 8%; n = 36; P < 0.0001;
Fig. 4b). This observation, along with the increased mitofu-
sin 2 (Mfn2) levels found in samples from cortical tissue in
the EMD, suggests a compensatory mechanism for the defi-
cient EMD mitochondria (Fig. 4c).
Discussion
In the present study, the potential role of megalin in the
energy homeostasis maintenance was investigated. Even
though it is expressed in several tissues, brain endothe-
lium is the only one endothelial tissue where megalin is
expressed simultaneously with Tie2. That situation makes
the Cre recombinase megalin deletion system specific to
brain endothelium. We demonstrate that the silencing of
megalin in the mouse brain endothelium is sufficient to
Fig. 2 Analysis of Obr and pSTAT3 expression in the hypothalamus. a Confocal images showing Obr (green) in neurons immunostained
with anti-NeuN (red) staining in EMD and control mice. Scalebar = 20 μm. b Percent of Obr+ cells that were NeuN+ diminished in EMD mice compared
to control mice. c Confocal images showing pSTAT3 (green), and NeuN (red) staining in EMD and control mice. Scalebar = 20 μm. d Quantitation of
pSTAT3-positive NeuN neurons in hypothalamic sections of EMD and control mice. Data are presented as mean ± SEM. ARC arcuate nucleus. *P < 0.05,
**P < 0.01; Student’s t test.
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increase the food intake, weight gain, and adiposity trig-
gering hyperleptinemia, hyperinsulinemia, increased tri-
glycerides blood levels, and impaired glucose tolerance.
Additionally, we provide evidences supporting the physio-
logical role of megalin in the regulation of energy balance
in agreement with previous data [15–17].
Fig. 3 EMD mice showed exacerbated cortical and hippocampal inflammation. a Higher expression of Iba-1 was observed in both cerebral cortex
and hippocampus in EMD mice compared to control mice. Scalebar = 20 μm. b Quantitative analysis of the number of Iba-1 stained cells was
performed in both brain areas. c Higher expression of GFAP was observed in both cerebral cortex and hippocampus in EMD mice compared to
control mice. Scalebar = 20 μm. d Quantitative analysis of the percentage area covered by GFAP immunoreactivity was performed in both brain
areas. Data are given as mean ± SEM. e mRNA cytokine expression was analyzed. Higher mRNA expression of interleukin (Il)-1β, Il-6, and tumor
necrosis factor (TNF-α) were observed in cerebral cortex and hippocampus in EMD mice compared to control mice. Neurogenesis impairment
due to increased inflammation is reflected in Additional file 1: Fig. S1. f Confocal images showing pSTAT3 (green) and NeuN (red) staining in EMD
and control mice. Scalebar = 20 μm. g Quantization of pSTAT3+ neurons was performed in cerebral cortex in EMD and control mice. h Unchanged
mRNA STAT3 expression was observed in both cerebral cortex and hippocampus in EMD mice compared to control mice. i mRNA SOCS3 expression
was analyzed in both cerebral cortex and hippocampus in EMD mice compared to control mice. Diminished mRNA expression of SOCS3 was observed
in both brain areas. j Higher mRNA expression of NPY was found in cerebral cortex from EMD mice compared to control mice. k Protein levels of leptin
were lower in EMD compared to control mice. Data are given as mean ± SEM. Cx cerebral cortex, Hip hippocampus. Data are presented as mean ±
SEM. *P < 0.05, **P < 0.01; Student’s t test.
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We reported here the first evidence that megalin
blockage in BBB endothelial cells reduce the brain leptin
uptake leading to hyperphagia and obesity. A recent re-
view summarizes a number of data showing that “West-
ern diets” enriched of saturated fatty acids and simple
carbohydrates contribute to degrade the BBB integrity
by reducing the expression of tight junction proteins,
particularly claudin 5 and 12 [18]. This BBB dysfunction
and disruption may be followed by leukocyte infiltration
into the brain causing or aggravating neuroinflammation.
Thus, in our experimental model we cannot exclude a dis-
ruption in the integrity of the BBB, as EMD mice share the
phenotype with other obesity mice models showing in-
creased levels of leptin, insulin and triglycerides in plasma,
and the contribution/side effects of inflammatory cell infil-
tration from blood into the brain. Our findings account for
the megalin expression in cerebral microvessel endothelial
cells which is capable to bind and endocyte leptin. More-
over, our results are in agreement with a recent study
suggesting megalin as the primary leptin transporter at
the BBB instead of ObR [19]. In this work, the authors
still detected leptin transport across monolayers of cul-
tured brain endothelial cells in the presence of a ObR-
neutralizing antibody [19]. Our previous findings
showed that blocking megalin expression in the choroid
plexus cells resulted in lower leptin levels in the cerebro-
spinal fluid caused by impairments in the leptin transport
[3]. Significantly high serum leptin levels were presented
Fig. 4 Mitochondrial impairments in the EMD mice cerebral cortex. a OXPHOS subunits in EMD and control mice. Representative OXPHOS bands
of cortical samples are shown (left panels). Protein levels of representative subunits of each of the five OXPHOS complexes were quantified (right panels). b
Mitochondrial mass assessment performed in different regions from cortical sections from all EMD and control mice. Quantitative analysis of fluorescence
targeting the ATP synthase β subunit revealed higher mitochondrial mass in EMD mice compared to control mice (left panels). c Representative western
blot is shown for mitofusin 2 (Mfn2). Right panel shows increased protein levels of Mfn2 in EMD mice compared to control mice. Data are presented as
mean ± SEM. *P< 0.05; Student’s t test.
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in obese subjects compared to a healthy control popula-
tion suggesting the leptin resistance as the main risk factor
to induce obesity [20, 21]. Studies showed that endothelial
specific leptin receptor knockout elicits persistent leptin
transport even increasing the leptin uptake into the brain
parenchyma [22, 23]. These findings could suggest an add-
itional leptin brain gate/transporter mediated by an alter-
native receptor/endocytic transporter other than ObR.
Our results suggest that blood leptin handle megalin to
cross the BBB reaching the neuronal receptors and trig-
gering the leptin signaling cascade as supports the reduced
STAT3 activation in the hypothalamic neurons from the
EMD mice. We also found reduced neuronal ObR expres-
sion in the EMD mice possibly as blood hyperleptinemia
consequence in agreement with previous studies [24].
The relationship between obesity-induced inflammation
and brain plasticity, particularly in the hippocampus and
frontal cortex, is highlighted by the enhanced astrocytic
and microglial activation and increased mRNA levels of
IL-1β, IL-6, and TNF-α in the cortex and the hippocam-
pus of EMD mice compared to the control. The obesity-
related glial upregulation has been found also in brain
regions involved in cognition and memory from patients
with clinical risk factors for stroke and obesity mouse
models [25, 26]. Neuroinflammation can be induced by
both CNS-intrinsic factors and systemic influences (fac-
tors from outside the CNS), resulting in peripheral
overproduction of pro-inflammatory cytokines, such as
IL-1β, IL-6, and TNF-. These circulatory inflammatory
mediators cross the BBB and may lead to CNS inflam-
mation, blocking intracellular signaling of molecules
such as insulin or leptin. Conversely, the activation of
glial cells results in a constant production of inflammatory
cytokines and chemokines by these cells, resulting in a
vicious circle affecting surrounding CNS cells, including
astrocytes and neurons, and finally causing neurodegener-
ation [27]. Additionally, the EMD mice showed increased
activation of STAT3. The activation of the JAK/STAT3
signaling pathway could be a downstream effect of the
CNS inflammation as occurs in neurodegenerative disor-
ders [28]. Altered IL-1β, IL-6, and TNF-α expression
levels activating the STAT3 pathway have been found in
brain inflammation models [29, 30]. Another upstream
player in the JAK/STAT3 pathway is the suppressor
SOCS3 which avoids the STAT3 phosphorylation [31].
Our data show reduced SOCS3 mRNA expression in the
EMD mice. SOCS3 blocks the upregulated expression of
inflammatory mediators, including IL-6, and it is down-
regulated in chronic inflammatory diseases [32, 33]. Our
results could indicate SOCS3-mediated pSTAT3 signaling
may be responsible to the continued production of cyto-
kines and the subsequent neuroinflammation found in the
EMD mice. Along with the reduced SOCS3, we found in-
creased NPY expression in the EMD mice, indicating
impaired leptin signaling pathway as it demonstrates the
reduced leptin levels. It is well established that leptin in-
duces SOCS3 expression and inhibits the NPY [34]. NPY
plays a role in a variety of basic physiological functions
and is also implicated regulating cognition, including anx-
iety, learning, and memory [35]. We previously demon-
strated increased anxiety behavior and impaired learning
ability and recognition in the memory in the EMD mice
[10] that could be related to the high NPY expression now
demonstrated in the cerebral cortex. Neuroinflammation
has been identified as a primary assaulting candidate for
impaired neurogenesis [36]. We propose the excessive re-
lease of inflammatory cytokines such as Il-1, Il-6, and
TNF-α, may be downregulating cell survival and differen-
tiation, and subsequently, neurogenesis. This has been fur-
ther documented by other studies where hippocampal and
hypothalamic neurogenesis was restored after blocking in-
flammatory signaling [37, 38].
A significant reduction in the complex I protein levels
were found in the EMD mice, suggesting possible ener-
getic disturbances. Modulating the mitochondrial quality
and function, leptin may control the cell bioenergetic
efficiency [39]. We can speculate that impaired leptin
signaling in the EMD mice may be responsible for mito-
chondrial disturbances suggesting a link between obesity
and brain mitochondrial dysfunction, and further, mice
learning impairments [38–41]. Neuroinflammation asso-
ciated with neurodegenerative diseases, like AD, is also
linked to mitochondrial impairment [39–41]. Thus,
EMD mitochondrial defects in EMD mice could be
related to central inflammation observed in these mice.
Along with the reduced complex I protein levels in the
EMD mice, increased mitochondrial mass were found in
the EMD mice brains compared to the control. The main-
tenance of mitochondrial homeostasis is central to keep
the neuronal viability and function. The higher mitochon-
drial mass observed in the EMD mice could compensate
the energy depletion as a consequence of complex I fail-
ure. Similar observations were found in muscle tissue
from rats where a reduction in OXPHOS efficiency
induced enhanced mitochondrial biogenesis as mitochon-
drial adaptation [42]. We additionally found increased
Mfn2 levels in brains from the EMD mice. Increased
Mfn2 levels could indicate enhanced mitochondrial
biogenesis as has been previously demonstrated Mfn2 reg-
ulates this process. [43, 44].
Conclusions
Our findings demonstrate that the EMD mice constitute a
valuable obesity model, linking obesity and neurodegener-
ation. Here, we demonstrate deletion of megalin in brain
endothelial cells to be a novel mechanism to promote
obesity and to activate obesity-induced neuropathological
mechanisms.
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Additional file
Additional file 1: Figure S1. EMD mice showed exacerbated
hypothalamic inflammation. (A) Higher expression of Iba-1 was observed
in arcuate hypothalamic nucleus in EMD mice compared to control mice. (B)
Quantitative analysis of the percentage area covered by Iba-1 immunoreactivity
was performed in this brain area. (C) Higher expression of GFAP was observed
in arcuate hypothalamic nucleus in EMD mice compared to control mice. (D)
Quantitative analysis of the percentage area covered by GFAP
immunoreactivity was performed in this brain area. Arc arcuate hypothalamic
nucleus. Data are presented as mean ± SEM. ** P < 0.01; Student’s t test.
Figure S2. Hippocampal NPY and leptin expression in EMD mice. (A) mRNA
expression of NPY was unchanged in hippocampal samples from EMD mice
compared to control mice. (B) Protein levels of leptin were unaffected in EMD
compared to control mice. Data are given as mean ± SEM. Figure S3.
Neurogenesis is reduced in EMD mice. (A) Representative photomicrographs
of DCX (red) and DAPI nuclei (blue) staining in the hippocampal granule cell
layer of EMD (n = 8), and control (n = 7) mice. Scalebar = 20 μm. (B) Number
of DCX+ cells in the DG of hippocampus is reduced in EMD mice compared
to control mice. (C) Fluorescent immunostaining for PSA-NCAM mainly
localized in the middle and inner cell layers of the dentate gyrus in EMD
(n = 8) and control (n = 7) mice. Scalebar = 20 μm. (D) PSA-NCAM+ cell
number is reduced in the DG of hippocampus in EMD mice compared to
control mice. Data are presented as mean ± SEM. DG dentate gyrus.
*P < 0.05, **P < 0.01; Student’s t test. Related to Fig. 3. Table S1. primers
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